Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry.
Lori B DanielsJunting RenKris KumarQuan M BuiJing ZhangXinlian ZhangMariem A SawanHoward EisenChristopher A LonghurstKaren MesserPublished in: PloS one (2021)
Patients taking statins prior to hospitalization for COVID-19 had substantially lower odds of death, primarily among individuals with a history of CVD and/or hypertension. These observations support the continuation and aggressive initiation of statin and anti-hypertensive therapies among patients at risk for COVID-19, if these treatments are indicated based upon underlying medical conditions.
Keyphrases
- coronavirus disease
- cardiovascular disease
- sars cov
- blood pressure
- end stage renal disease
- coronary artery disease
- healthcare
- respiratory syndrome coronavirus
- chronic kidney disease
- type diabetes
- ejection fraction
- newly diagnosed
- heart failure
- peritoneal dialysis
- prognostic factors
- atrial fibrillation
- cardiovascular events
- cardiovascular risk factors
- patient reported